Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Biofrontera Inc. reported Fiscal year ending December 31, 2022 results: revenue total revenues for 2022 to increase between 24% and 31% compared with 2021. Guidance initiated.
- Period
- Fiscal year ending December 31, 2022
- Revenue
- total revenues for 2022 to increase between 24% and 31% compared with 2021
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
With year-to-date revenues up 24%, we expect total revenues for 2022 to increase between 24% and 31% compared with 2021, inclusive of seasonal strength in the first and fourth quarters.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Biofrontera Inc. reported Third quarter ended September 30, 2022 results: revenue Total revenues $4.3 million, net income Net loss $2.6 million, EPS $0.11 per share.
- Period
- Third quarter ended September 30, 2022
- Revenue
- Total revenues $4.3 million
- Net income
- Net loss $2.6 million
- EPS
- $0.11 per share
- Result
- reported results
Exact text from the filing
Total revenues for the third quarter of 2022 of $4.3 million were consistent with the third quarter of 2021. Total operating expenses were $8.0 million for the third quarter of 2022, compared with $20.4 million for the third quarter of 2021. Cost of revenues decreased by 3% primarily due to lower Ameluz sales. Selling, general and administrative expenses decreased by $9.3 million, or 54%, compared with the prior year primarily due to a one-time legal settlement expense in 2021, partially offset by higher business insurance and headcount costs as a result of resumed hiring in 2022. Net loss for the third quarter of 2022 was $2.6 million, or $0.11 per share, compared with a net loss of $16.0 million, or $2.00 per share, for the third quarter of 2021.
View on SEC.gov